Last reviewed · How we verify

TEMOCAPRIL

FDA-approved active Small molecule Under review Quality 17/100

TEMOCAPRIL is a temocapril drug. It is currently FDA-approved for Hypertensive disorder.

Temocapril is a small molecule with a mechanism of action related to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. It has been studied in a real-world retrospective cohort study for its association with post-stroke pneumonia.

At a glance

Generic nameTEMOCAPRIL
Drug classtemocapril
TargetAngiotensin-converting enzyme
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TEMOCAPRIL

What is TEMOCAPRIL?

TEMOCAPRIL is a temocapril drug, indicated for Hypertensive disorder.

What is TEMOCAPRIL used for?

TEMOCAPRIL is indicated for Hypertensive disorder.

What drug class is TEMOCAPRIL in?

TEMOCAPRIL belongs to the temocapril class. See all temocapril drugs at /class/temocapril.

What development phase is TEMOCAPRIL in?

TEMOCAPRIL is FDA-approved (marketed).

What does TEMOCAPRIL target?

TEMOCAPRIL targets Angiotensin-converting enzyme and is a temocapril.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing